



Twenty Years of Get With The Guidelines-Stroke: Celebrating Past Successes, Lessons Learned, and Future Challenges

Mathew J. Reeves¹, PhD; Gregg C. Fonarow², MD; Eric E. Smith³, MD; Kevin N. Sheth⁴, MD; Steven R. Messe, MD; Lee H. Schwamm⁵, MD

ABSTRACT: The Get With The Guidelines-Stroke program which, began 20 years ago, is one of the largest and most important nationally representative disease registries in the United States. Its importance to the stroke community can be gauged by its sustained growth and widespread dissemination of findings that demonstrate sustained increases in both the quality of care and patient outcomes over time. The objectives of this narrative review are to provide a brief history of Get With The Guidelines-Stroke, summarize its major successes and impact, and highlight lessons learned. Looking to the next 20 years, we discuss potential challenges and opportunities for the program.

Key Words: program development ■ quality improvement ■ quality of health care ■ registries ■ stroke ■ treatment outcome

The Get With The Guidelines (GWTG)-Stroke program or registry was developed with the principal aim of improving the quality of care and outcomes of patients hospitalized with acute stroke. Prior reports provide details of the program's origins, development, organization, and structure.¹⁻⁵ In brief, GWTG-Stroke began in 2001 when the American Heart Association (AHA) introduced a pilot quality improvement (QI) registry for stroke, based in part on the success of existing programs in coronary artery disease.^{6,7} After becoming a national program in 2003, GWTG-Stroke grew rapidly. By August 2009, there were 1419 participating hospitals with data captured on 1 million stroke and TIA admissions.³ In 2023, the registry now includes 9 million patient records submitted by over 2600 participating hospitals, a level of growth that greatly exceeded expectations.

Several factors contributed to the establishment of a national QI-based stroke registry. A major driver were challenges in implementing intravenous (IV) thrombolysis (tPA) therapy, which had received FDA approval in 1995. Another driver was the development in 2004 of AHA strategic impact goals to reduce heart disease

and stroke risk by 25% by 2020.⁸ These goals would depend in part on secondary prevention medications (eg, antiplatelet, antihypertension, and statins), which were known to be suboptimal in many clinical populations.^{9,10} Other factors that were foundational to establishing GWTG-Stroke include the AHA's Metro Stroke and Operation Stroke programs that began in 1998,⁵ the Brain Attack Coalition recommendations in 2000 on primary stroke centers,¹¹ and funding from the Centers for Disease Control to establish the Paul Coverdell National Acute Stroke Registry in 2001.¹²

At the foundation of the registry is a data-driven approach to translate evidence and guidelines into clinical practice.¹³ From its inception, the program was developed around the concept of a collaborative learning model that encourages hospitals to improve care by changing how they do things. Important features of the program include concurrent data collection and clinical decision support, as well as interactive learning modules and teleconferences that share data and QI strategies with hospitals.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

Correspondence to: Mathew J. Reeves, PhD, Department of Epidemiology and Biostatistics, Michigan State University, B601 W Fee Hall, E Lansing, MI 48824. Email reevesm@msu.edu

This manuscript was sent to Liping Liu, Guest Editor, for review by expert referees, editorial decision, and final disposition.

For Sources of Funding and Disclosures, see page 1695.

© 2024 The Authors. *Stroke* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Stroke is available at www.ahajournals.org/journal/str

WHAT ARE THE NOTABLE SUCCESSES AND OVERALL IMPACT OF THE GWTG-STROKE PROGRAM?

Improved Quality of Care Leading to Better Patient Outcomes

Analyses of data collected by GWTG-Stroke hospitals have demonstrated that participation in the program is associated with sustained improvements in the quality of care. Two early papers showed strong temporal trends in improved care processes and endorsed performance metrics.^{2,3} Over the initial 5-years of the program, the IV tPA treatment rate among eligible patients arriving within 2 hours from the last known well increased from 42% to 73%, smoking cessation counseling increased from 74% to 88%, and DVT prophylaxis increased from 74% to 90%.² Treatment rates for antithrombotic and anticoagulation medications that had high compliance at baseline continued to show improvements, achieving almost 100% compliance in later years.^{2,3} Several subsequent publications showed either continued improvements or sustained high levels of care compliance on key measures.^{14–19} Early papers also highlighted disparities in care quality across different race/ethnic groups^{20,21} and by sex,²² while others focused on developing risk scores,^{23,24} or demonstrating the association between improved care and better patient outcomes.^{25–27} We highlight 2 important analyses that compared quality of care and patient outcomes among hospitals that either did or did not participate in the GWTG-Stroke program. In the first study, data from the population-based REGARDS study (Reasons for Geographic and Racial Differences in Stroke) showed that ischemic stroke patients admitted to GWTG-Stroke hospitals received higher quality care than stroke patients who were admitted to nonparticipating hospitals.²⁸ In the second study, analysis showed that hospitals that joined the GWTG-Stroke program produced faster gains in patient-centered outcomes, including increased discharge to home and reductions in mortality, compared with similar hospitals that had not joined the program.²⁷ In the absence of data generated from randomized controlled trials, these findings provide the strongest available evidence for the impact of the GWTG-Stroke program on producing better quality of care and improved patient outcomes.

Contributions to the Development of Stroke Systems of Care

Over the last 20 years, GWTG-Stroke has become an integral part of the development of the nationwide stroke systems-of-care model, resulting in a complete redesign of the acute stroke care delivery system in the United

States.^{29–31} As mentioned earlier, while other organizations and programs,^{11,32} including hospital certification,³³ have been critical to the development of a new systems-of-care model, the size and reach of the GWTG-Stroke program along with the data it provides have made a significant contribution to the effort. Notably, GWTG-Stroke reports that have addressed relevant system-level factors at the prehospital,^{15,34,35} hospital,^{36–39} posthospital, and regional levels^{40–43} have been essential for motivating action and policy changes at the systems level, as well as at individual hospital, practice, and agency levels. Data from GWTG-Stroke document how changes in the stroke system of care have translated into greater access to endovascular therapy (EVT)¹⁷ with reduced disparities across age, race, and sex.^{44–46} The importance of hospital certification for EVT access and outcomes is illustrated by a recent GWTG-Stroke report that shows higher care quality and better outcomes for EVT patients treated at comprehensive or thrombectomy-capable stroke centers.⁴⁷

Establishing a Community of Researchers Responsible for Broad Dissemination of Registry Findings

When the GWTG-Stroke program was first established, the AHA organized an oversight committee consisting of AHA staff, external stakeholders, and academic partners including stroke clinicians, health services researchers, and statisticians. The committee served to provide scientific guidance to the program, to develop project ideas, and to oversee the analysis, write-up, and dissemination of research findings. This multi-disciplinary committee has evolved into a community of like-minded researchers that has fostered a team-based approach characterized by high levels of productivity. Since the first analyses of GWTG-Stroke data were published in 2005, the GWTG-Stroke website currently lists 173 peer-reviewed publications with between 10 and 15 new papers added each year.⁴⁸

Promotion of Hospital QI Efforts

A central goal of the GWTG-Stroke program is to improve the quality of care delivered to patients hospitalized with acute stroke. To achieve this, the program has taken a proactive approach to engaging with hospitals to help them undertake QI initiatives, which has included alternative methods of information dissemination to front-line hospital staff (who do not always access the peer-reviewed literature). The GWTG-Stroke website⁴⁸ includes an array of educational tools, including webinars, workshops, and online mini-learning series where new registry findings are disseminated to hospital staff. The website also

includes a range of resources designed to promote the implementation of QI programs, including specific data submission forms, clinical tools, and checklists. The success of this approach is illustrated by the Target Stroke QI campaigns,⁴⁹ which developed a range of toolkits specifically designed to help hospitals identify and solve barriers to the timely administration of IV tPA.^{50,51} Details of the results of Target Stroke are reviewed further below.

Influence on Other Disease Registries and QI Programs

Of the 5 disease-specific QI registries overseen by the AHA, GWTG-Stroke is by far the largest in terms of both the number of participating hospitals (n=2635; Figure 1) and the total number of discharges recorded (\approx 9 million; Figure 2). The success of the GWTG-Stroke registry (along with the AHA's heart failure and coronary heart disease modules) provided the impetus to expand the AHA's disease-specific registries to include cardiac resuscitation and atrial fibrillation. More broadly, the success of the GWTG-Stroke program has been one of the drivers for the expansion of QI-based stroke registries across the globe,⁵² including successful replications of the GWTG-Stroke registry in other countries, including Taiwan⁵³ and China.⁵⁴

WHY HAS THE GWTG-STROKE PROGRAM BEEN SO SUCCESSFUL? WHAT ARE THE LESSONS LEARNED?

Hospital Stroke Certification and the Need for Data

A key driver of the sustained growth of GWTG-Stroke was the establishment of hospital stroke certification programs by the Joint Commission,⁵³ other hospital certifying organizations,⁵⁵ and state-level programs. To obtain and maintain certification, hospitals need to submit performance data confirming that they are providing high-quality care (as indicated by meeting endorsed benchmarks on specific performance measures). For both primary and comprehensive stroke centers, the collection and submission of ongoing performance data (as curated by GWTG-Stroke) and participation in ongoing QI initiatives (as facilitated by GWTG-Stroke) became essential components of their work.^{11,56} A critically important step in the development of this data-driven certification system was the establishment of a harmonized set of stroke performance measures,⁵⁷ which was endorsed by AHA, the Centers for Disease Control, and quality assurance programs including the Joint Commission and the National Quality Forum.⁴ A subset of these measures were subsequently selected by the Centers of Medicare Services as candidates for use in




Figure 1. Geographic distribution of hospitals participating in Get With The Guidelines-Stroke between 2005 and 2023 (n=2635).




Figure 2. Cumulative number of stroke discharges (in millions) captured in the Get With The Guidelines-Stroke program between 2005 and 2023.

various hospital pay-for-reporting and pay-for performance programs,⁵⁸ although the final adoption of stroke-specific measures has been limited to date. In summary, the adoption by several key health care agencies, certifying bodies, and funders of a standardized set of stroke performance measures that required careful ongoing patient-level documentation by hospitals helped ensure the broad adoption of the GWTG-Stroke program, which had been specifically designed to facilitate the collection and reporting of these very measures. The key lesson learned is that it was vital for AHA to establish working partnerships with agencies and stakeholders involved in the promotion of high-quality acute stroke care as well as the redesign of stroke systems of care. Furthermore, ensuring that the hospital certification process relied on data-driven metrics provided further incentive for hospitals to participate in GWTG-Stroke.

Recognizing Hospital Success Through GWTG-Stroke Awards

From early on, the AHA recognized the importance of formally acknowledging the work of individual hospital teams by establishing a recognition program.⁵⁹ The GWTG-Stroke recognition program is structured around 3 tiers of award levels (bronze, silver, and gold), which identify hospitals that have achieved high levels of quality care over either a 3-month, 1-year, or 2-year time period. A high level of care is defined as achieving 85% compliance on 7 endorsed stroke performance measures. Hospital achievement awards are announced annually at a celebration at the International Stroke Conference, posted on the GWTG-Stroke website, and published in a special issue of the US News and World Report. Much of the success at the individual hospital level to improve care comes down to the hard work and commitment of a small

number of team members. The public recognition of the work of hospital staff serves as an important motivator to sustain team efforts and affords them the opportunity to highlight their work to their own hospital leadership. Moreover, through advertising and marketing efforts, individual hospitals can use these awards to promote their work to local and regional communities. Thus, another key lesson learned is that recognizing the work of hospitals and hospital QI teams is an important component to sustaining the growth and continued high levels of hospital participation seen in the GWTG-Stroke registry.

Identifying Opportunities for QI

To address its central mission of improving the quality of acute stroke care, the GWTG-Stroke program has highlighted important gaps in care that have led to targeted QI projects being implemented across the registry. The best example of this is the highly successful Target Stroke campaign. While early data from GWTG-Stroke found a dramatic increase in the proportion of ischemic stroke patients treated with IV tPA,² faster time to treatment is strongly correlated with improved outcome, and only about a quarter of treated patients received the drug within 60 minutes of hospital arrival. Moreover, this time metric was static and had not meaningfully improved despite an increase in the overall treatment rates.³⁷ The first Target Stroke Quality Improvement Project had the goal of doubling the proportion of tPA-treated patients with a door-to-needle time of <60 minutes to 50%.⁶⁰ The results of this first campaign were striking; the program met its goal by the end of the 3-year intervention period when the proportion of patients with a door-to-needle ≤60 minutes reached 53%.⁶¹ Importantly, this reduction in time to treatment was associated with lower rates of

symptomatic intracranial hemorrhage and in-hospital mortality and a greater likelihood of discharge home. The success of this first Target stroke project led to 2 additional campaigns to further reduce treatment delays.⁶² The current Target Stroke III campaign seeks to achieve both shorter door-to-needle times for IV tPA and shorter door-to-device times for EVT.⁴⁹ The important lesson learned is the need for a QI program to identify the most important gaps in quality of care (in this case, the slow delivery of tPA) and to follow this up with an aggressive QI campaign designed to show rapid improvements in care. The effectiveness of the Target Stroke campaign was in large part due to the development and dissemination of specific QI tools and materials designed to speed up the delivery of tPA⁴⁸; similar benefits are anticipated in the timeliness of EVT now that it has been included in the latest Target Stroke campaign.

Developing Young Investigators and Facilitating Data Access

The large number of people who have coauthored GWTG-Stroke papers, including many junior investigators, has been facilitated by having an open process to submit ideas for specific hypothesis-driven analyses, along with specific funding to support applications from early-career investigators.⁶³ More recently, online access to de-identified GWTG-Stroke data has been established through the AHA's Precision Medicine Platform.⁶⁴ The important lesson learned was the need for the program to actively promote the involvement of young investigators and to take specific steps to democratize data access. These steps have increased the reach and availability of the GWTG-Stroke data to interested researchers across the globe.

WHAT DOES THE FUTURE BRING? CHALLENGES AND OPPORTUNITIES

The Table summarizes several potential future threats and opportunities for the continued success of the GWTG-Stroke program.

CONCLUSIONS

The GWTG-Stroke registry represents a major success story given its impact on stroke care in the United States. The participation of so many US hospitals over the past 20 years has resulted in a large, nationally representative database that has demonstrated sustained increases in both the quality of care and patient outcomes over time. GWTG-Stroke has played a central role in the redesign of stroke systems of care including hospital certification, performance measure development, and pay-for-reporting programs. Several features of GWTG-Stroke can serve as

Table. Summary of Potential Challenges and Opportunities for the GWTG-Stroke Program

Potential challenges
<p>1. Inability of hospitals to sustain abstractor-based data collection</p> <p>Although most registries still rely on manual data collection and curation, it is well recognized that this requires substantial resources in terms of human capital, costs, and time.⁶⁵ The potential for registry data to be mined from electronic medical record (eMR) data is therefore very appealing and holds the potential to increase efficiency and timeliness of data access.⁶⁶ Improving the efficiency of data collection would help ensure hospitals continue to participate in clinical registries. However, considerable practical challenges exist in terms of incorporating eMR data into clinical registries, including system interoperability, data accuracy and completeness, lack of important clinical information (eg, contraindications), patient privacy, and data governance.^{67,68} Thus, while increased integration of eMR data into Get With The Guidelines (GWTG)-Stroke would help lessen the burden of data abstraction, there remains a need for human operators to conduct manual data abstraction, curation, and monitoring.⁶⁸ However, the development of artificial intelligence (AI) tools that autocomplete data collection could change this situation.</p>
<p>2. Changes to privacy regulations and increased proprietary ownership of patient data</p> <p>All participating GWTG-Stroke hospitals are required to comply with local regulatory and privacy guidelines and secure institutional review board approval. GWTG-Stroke is first and foremost a QI registry; because research is a secondary objective and occurs exclusively using de-identified data, federal regulatory policies assuring ethical and privacy standards (ie, the Common Rule and the Privacy Rule) are judged to not apply.^{65,69} Most participating sites are therefore able to obtain either an exemption from human subjects review or a waiver of authorization such that individual patient consent is not required. However, future changes to the legal application of these policies to QI registries could threaten the current functioning of GWTG-Stroke. Several examples exist demonstrating how changes to the interpretation of existing regulatory policies have directly impacted disease registries.⁶⁹ A study from Canada illustrated how the introduction of requirements for individual patient consent had a dramatic negative effect on the representativeness and efficiency of a stroke registry.⁷⁰ It could also be argued that ongoing concerns about the ethical and regulatory standing of registries like GWTG-Stroke continue to stifle innovation. The linkage of registry data to external data sources (eg, claims) or the collection of patient-reported outcomes data following discharge are both complicated by the absence of individual patient consent. It is clear that the digital health care environment of today is very different from when GWTG-Stroke started 20 y ago. The potential to share content from large health databases with third-party technology companies, along with illicit security breaches of personal data, have raised concerns about the effectiveness of current privacy regulations.⁷¹ Moreover, concepts of the quantified self⁷² and patient ownership of their own health data⁷³ raise important but challenging questions related to data privacy, ownership, and patient consent. These and other changes to the current health data environment will continue to test the functioning and structure of disease registries in the future.</p>
<p>3. Exclusion of stroke from Centers of Medicare Services (CMS) payment reform and QI initiatives</p> <p>Over the past decade, CMS has implemented several national payment reform and QI programs, including value-based purchasing and readmission reduction programs targeted at hospitals.⁵⁸ However, these 2 programs are currently limited to just 4 disease conditions (acute myocardial infarction, pneumonia, heart failure, and chronic obstructive pulmonary disease). Although stroke is included in the inpatient quality reporting program, this is limited to the public reporting of hospital-specific 30-d stroke mortality rates. The lack of emphasis on stroke in these CMS programs could be a potential risk to the GWTG-Stroke registry if it were to lead to hospitals dropping out of the registry because they do not see a benefit to tracking the quality of care for acute stroke patients.</p>

(Continued)

Table. Continued

Potential challenges
Potential opportunities
1. Contributions from GWTG-Stroke data to the learning health system (LHS) framework
The concept behind the LHS is that health care systems can be redesigned so that they better use health information technology to optimize health care delivery. ^{74,75} Disease registries such as GWTG-Stroke can play a central role in the LHS concept because they can provide data that feeds a continuous learning cycle whereby "evidence informs practice" and "practice informs evidence." ⁷⁴ However, while there is clear overlap in the mission and functions of LHS and disease-specific QI-based registries, critical evaluation has found few tangible examples where GWTG-Stroke data are being applied to the LHS concept. ⁷⁵ This gap represents an opportunity for GWTG-Stroke to align its data organization and processing so that it can be more readily used within the LHS framework. Case studies highlighting the application of GWTG-Stroke data by hospitals and health systems within the LHS framework would be valuable.
2. Automated data collection and real-time clinical decision support
The recent advent of cloud storage and high-performance computing is revolutionizing data sciences and predictive analytics. These tools, along with generative AI tools powered by large language models, like GPT-4, promise to transform the way that health care is delivered. For example, GPT-4 outperformed medical-journal readers in diagnosing complex medical case challenges, ⁷⁶ and custom large language models are now being deployed to use ambient listening to draft clinical notes and health portal message replies. These tools will also soon be able to suggest guideline-based care protocols to patients in real time, including personalized secondary stroke prevention based on pharmacogenetics. Other applications include AI-driven prediction models to improve post-discharge medication adherence or flag high-risk patients for enhanced monitoring to prevent readmission. The potential for AI-based tools to autocomplete data collection and thus greatly improve the efficiency of registries was mentioned earlier. Ultimately, how clinical registries leverage the power of AI so that they remain relevant but distinct from eMR data remains a key unknown.
3. Development of a patient self-management tool
Improving self-management skills in stroke survivors plays a critical role in improving secondary prevention of stroke (through medication adherence, risk factor control, and lifestyle change), while also promoting stroke recovery. ⁷⁷ Because self-management requires ongoing training and engagement, eHealth-based technologies offer appealing, low-cost, and adaptable solutions to provide patient education, engagement, and risk factor control. ^{78,79} The AHA is currently pilot testing a mobile phone-based self-management tool to assist stroke patients (and caregivers) with their transition home following hospital discharge. ⁸⁰ The tool includes a menu of curated educational materials, social support resources, symptom and risk factor tracking, medication management, and health self-assessments. Goal-setting options that target changes in lifestyle and risk factors are also provided. Importantly, future versions of the tool will offer the ability to incorporate patient-specific data from the GWTG-Stroke registry itself and potentially allow for the online collection of patient-reported outcomes.
4. Big data and opportunities for data linkage
Data generated by disease registries such as GWTG-Stroke have many of the cardinal features of big data, including large patient volumes, a broad variety of stroke subtypes, and the rapid availability of data. ⁸¹ However, a major limitation of GWTG-Stroke is the lack of follow-up data needed to identify readmissions, stroke recurrence, and deaths. Data linkage between registry data and claims data offers the opportunity to track patients posthospitalization. ⁸² Outcome events could also be tracked by linking registry and eMR data. ⁸³ However, the ideal solution would be to develop unique patient identifiers that allow for linkage across hospitalizations and between hospital systems to provide a comprehensive picture of patient outcomes and utilization.

(Continued)

Table. Continued

Potential challenges
5. Generating population level surveillance data at national level
The United States lacks a timely and comprehensive surveillance system to track the burden of cardiac disease and stroke. ⁸³ A recent study illustrated how GWTG-Stroke data can be repurposed as a surveillance resource by reweighting the data so it represents nationally representative data. ⁸⁴ The ability of GWTG-Stroke registry data to provide more timely and nationally representative data on stroke hospitalization, including clinical care and outcomes, represents an important opportunity to better quantify the national stroke burden.
6. Addressing health disparities through social determinants of health (SDOH)
Registries play an important role in addressing gaps in care related to health care disparities ^{4,68} and in examining the role of SDOH. GWTG-Stroke publications have identified disparities in quality of care across different race/ethnic groups ^{20,21} and by sex, ²² while others have examined the effect of insurance status on disparities in both access to care and outcomes following stroke. ^{21,85,86} Analyses of GWTG-Stroke data have also shown evidence of reduced disparities over time in access to EVT treatment by age, ⁴⁴ race, ⁴⁵ and sex. ⁴⁶ While GWTG-Stroke collects demographic data (age, sex, race/ethnicity, and insurance) that are often used as proxies for disadvantaged populations, it has not been able to collect more detailed SDOH data such as education, income, housing insecurity, sexual orientation, or perceived levels of discrimination. However, opportunities now exist to include these important variables in GWTG-Stroke. First, GWTG has recently included several new data fields that expand available patient-level information on SDOH, including gender identification and unmet social needs. Second, external data linkage offers an important opportunity to examine neighborhood-level SDOH data. For example, currently, efforts are ongoing to analyze census-derived SDOH data that have been linked to GWTG-Stroke, including education, employment, and poverty. Given the emphasis now being given to addressing SDOH ⁸⁷ and structural racism, ⁸⁸ opportunities to examine SDOH data will likely continue to expand in GWTG-Stroke and will hopefully lead to further reductions in disparities in stroke care and outcomes.
7. Embedded registry-based randomized clinical trials
There are ongoing challenges to conducting randomized clinical trials given the required infrastructure, administrative burden, poor efficiency, frequent delays, and excessive costs. Conducting clinical trials within established clinical registries like GWTG-Stroke offers the possibility of reducing many of these barriers. ⁸⁹ The size of GWTG-Stroke, along with its robust data collection mechanisms and broad patient inclusion criteria, offer ideal starting conditions to implement pragmatic trials at scale with greater efficiency. Examples of trials and comparative effectiveness studies conducted within GWTG-Stroke include MaRISS, PROSPER, CHANGE AFib, and ARAMIS. ⁹⁰
8. Collection of cost data
There are at least 2 areas where the collection of cost data in GWTG-Stroke would make meaningful contributions. First, although largely undefined, costs to support the necessary data management resources required for individual hospitals to abstract and curate clinical data for disease registries are thought to be significant. ⁸⁸ An important contribution of GWTG-Stroke would be to obtain detailed data on the operational costs of participating in the registry, ⁹¹ which could then be used to generate cost-effectiveness estimates of program participation. ⁶⁵ Second, GWTG-Stroke could play an important role by collecting data on hospital costs. The United States has the highest average per-patient costs for stroke in the world, ⁹² but United States estimates of the cost of stroke vary dramatically, driven largely by differences in the populations studied and the cost-related methods utilized. ^{93,94} To date, the cost data available to GWTG-Stroke have been limited to Medicare fee-for-service claims, but as Medicare Advantage plans continue to expand, fee-for-service claims will represent an ever smaller proportion of admissions. Large representative hospital-based registries like GWTG-Stroke could provide data on hospital costs that could help fill the void of cost-of-care and cost-effectiveness studies in the United States. ⁹⁵

ARAMIS indicates Addressing Real-World Anticoagulant Management Issues in Stroke Registry; CHANGE AFib, Change Afib Pragmatic Stroke Prevention trial; GPT-4, Generative Pre-Trained Transformer- 4; MaRISS, Mild and Rapidly Improving Stroke Study; and PROSPER, Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research.

models for other QI-based registries, including the development of targeted QI interventions, the hospital awards program, the broad dissemination of research findings, and the promotion of junior investigators. However, the technological and regulatory environments affecting health care data in the United States are ever-changing, and the registry needs to continue to be vigilant for both future opportunities and challenges to its position as one of the most important disease registries in the United States. This includes the willingness to change its organization, function, and structure as external forces dictate.

ARTICLE INFORMATION

Affiliations

Department of Epidemiology and Biostatistics, Michigan State University, East Lansing (M.J.R.). Division of Cardiology, Geffen School of Medicine, University of California Los Angeles (G.C.F.). Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Alberta, Canada (E.E.S.). Center for Brain & Mind Health, Departments of Neurology & Neurosurgery (K.N.S.) and Department of Neurology and Bioinformatics and Data Sciences (L.H.S.), Yale School of Medicine, New Haven, CT. Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia (S.R.M.).

Acknowledgments

The authors thank all the American Stroke Association staff members who have contributed to the program over the past 20 years as well as members of the Get With The Guidelines--Stroke Systems of Care Advisory group, Duke Clinical Research Institute, Outcome Sciences/IQVIA, and the many participating hospitals, health professionals, and data abstractors.

Sources of Funding

The Get With The Guidelines (GWTG)-Stroke program is provided by the American Heart Association. GWTG-Stroke has been or is currently sponsored, in part, by Alexion, AstraZeneca Rare Disease, ARAMIS, AstraZeneca, Bayer, Boehringer Ingelheim and Eli Lilly Diabetes Alliance, Boehringer-Ingelheim, Boehringer-Ingelheim Lilly, Bristol-Myers Squibb, Bristol-Myers Squibb/ Sanofi Pharmaceuticals Partnership, Chiesi Pharmaceuticals, Daiichi Sankyo, Eli Lilly and Company, Genentech, Glaxo Smith-Kline, HCA Healthcare, Janssen Pharmaceutical Companies, Johnson & Johnson, Medtronic, Merck, Merck-Schering Plough, Merck-Schering Plough Pharmaceutical, National Institute of Diabetes and Digestive and Kidney Diseases, Novartis, Novo Nordisk, Patient-Centered Outcomes Research Institute, Pfizer Inc, Portola Pharmaceuticals, Sanofi, and Tyleneol.

Disclosures

Dr Fonarow reports consulting for Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Janssen/Johnson & Johnson, Medtronic, Merck, Novartis, and Pfizer. Dr Messe reports consulting for Terumo and EmStop, a provisional patent for a stroke monitor, which has been licensed to Neuralert Technologies, and equity in Neuralert Technologies. Dr Sheth reports grant support from National Institutes of Health, American Heart Association, and Hyperfine; consulting from Astrocyte, CSL Behring, Rhaeos, Cerevasc, Bexorg Sense and Philips Data and Safety Monitoring Board; and patent with Alva. The other authors report no conflicts.

REFERENCES

- LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. *Arch Intern Med*. 2008;168:411–417. doi: 10.1001/archinternmed.2007.101
- Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, Ellrodt G, Cannon CP, Liang L, Peterson E, et al. Get With The Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. *Circulation*. 2009;119:107–115. doi: 10.1161/CIRCULATIONAHA.108.783688
- Fonarow GC, Reeves MJ, Smith EE, Saver JL, Zhao X, Olson DW, Hernandez AF, Peterson ED, Schwamm LH; GWTG-Stroke Steering Committee and Investigators. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in get with the guidelines-stroke. *Circ Cardiovasc Qual Outcomes*. 2010;3:291–302. doi: 10.1161/CIRCOUTCOMES.109.921858
- Ellrodt AG, Fonarow GC, Schwamm LH, Albert N, Bhatt DL, Cannon CP, Hernandez AF, Hlatky MA, Luepker RV, Peterson PN, et al. Synthesizing lessons learned from Get With The Guidelines: the value of disease-based registries in improving quality and outcomes. *Circulation*. 2013;128:2447–2460. doi: 10.1161/01.cir.0000435779.48007.5c
- Ormseth CH, Sheth KN, Saver JL, Fonarow GC, Schwamm LH. The American Heart Association's Get With The Guidelines (GWTG)-Stroke development and impact on stroke care. *Stroke Vasc Neurol*. 2017;2:94–105. doi: 10.1136/svn-2017-000092
- Fonarow GC, Gawlinski A, Moughrabi S, Tillich IH. Improved treatment of coronary heart disease by implementation at a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). *Am J Cardiol*. 2001;87:819–822. doi: 10.1016/s0002-9149(00)01519-8
- Lewis WR, Peterson ED, Cannon CP, Super DM, LaBresh KA, Quealy K, Liang L, Fonarow GC. An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program. *Arch Intern Med*. 2008;168:1813–1819. doi: 10.1001/archinte.168.16.1813
- Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation*. 2010;121:586–613. doi: 10.1161/CIRCULATIONAHA.109.192703
- Jencks SF, Cueddon T, Burwen DR, Fleming B, Houck PM, Kussmaul AE, Nilasena DS, Ordín DL, Arday DR. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. *JAMA*. 2000;284:1670–1676. doi: 10.1001/jama.284.13.1670
- Holloway RG, Benesch C, Rush SR. Stroke prevention: narrowing the evidence-practice gap. *Neurology*. 2000;54:1899–1906. doi: 10.1212/wnl.54.10.1899
- Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, Starke RD, Todd HW, Viste KM, Girus M, et al. Recommendations for the establishment of primary stroke centers. *JAMA*. 2000;283:3102–3109. doi: 10.1001/jama.283.23.3102
- Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, Karp H, LaBresh KA, Malarcher A, Mensah G, et al; Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. *Stroke*. 2005;36:1232–1240. doi: 10.1161/01.STR.0000165902.18021.5b
- LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention - pilot results. *Arch Intern Med*. 2004;164:203–209. doi: 10.1001/archinte.164.2.203
- Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow GC. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. *Circ Cardiovasc Qual Outcomes*. 2013;6:543–549. doi: 10.1161/CIRCOUTCOMES.111.000303
- Tong D, Reeves MJ, Hernandez AF, Zhao X, Olson DM, Fonarow GC, Schwamm LH, Smith EE. Times from symptom onset to hospital arrival in the Get With The Guidelines-Stroke program 2002 to 2009: temporal trends and implications. *Stroke*. 2012;43:1912–1917. doi: 10.1161/STROKEAHA.111.644963
- Reeves MJ, Grau-Sepulveda MV, Fonarow GC, Olson DM, Smith EE, Schwamm LH. Are quality improvements in the Get With The Guidelines-Stroke program related to better care or better data documentation? *Circ Cardiovasc Qual Outcomes*. 2011;4:503–511. doi: 10.1161/circoutcomes.111.961755
- Menon BK, Saver JL, Goyal M, Nogueira R, Prabhakaran S, Liang L, Xian Y, Hernandez AF, Fonarow GC, Schwamm L, et al. Trends in endovascular therapy and clinical outcomes within the nationwide Get With The Guidelines-Stroke registry. *Stroke*. 2015;46:989–995. doi: 10.1161/STROKEAHA.114.007542
- O'Brien EC, Greiner MA, Xian Y, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL, Smith EE, Maisch L, Hannah D, et al. Clinical effectiveness of statin therapy after ischemic stroke: primary results from the statin

therapeutic area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. *Circulation*. 2015;132:1404–1413. doi: 10.1161/CIRCULATIONAHA.115.016183

19. Xian Y, Wu J, O'Brien EC, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL, Smith EE, Suter RE, Hannah D, et al. Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. *BMJ*. 2015;351:h3786. doi: 10.1136/bmj.h3786
20. Schwamm LH, Reeves MJ, Pan W, Smith EE, Frankel MR, Olson D, Zhao X, Peterson E, Fonarow GC. Race/ethnicity, quality of care, and outcomes in ischemic stroke. *Circulation*. 2010;121:1492–1501. doi: 10.1161/CIRCULATIONAHA.109.881490
21. James ML, Grau-Sepulveda MV, Olson DM, Smith EE, Hernandez AF, Peterson ED, Schwamm LH, Bhatt DL, Fonarow GC. Insurance status and outcome after intracerebral hemorrhage: findings from Get With The Guidelines-Stroke. *J Stroke Cerebrovasc Dis*. 2014;23:283–292. doi: 10.1016/j.jstrokecerebrovasdis.2013.02.016
22. Reeves MJ, Fonarow GC, Zhao X, Smith EE, Schwamm LH; Get With The Guidelines-Stroke Steering Committee & Investigators. Quality of care in women with ischemic stroke in the GWTG program. *Stroke*. 2009;40:1127–1133. doi: 10.1161/STROKEAHA.108.543157
23. Smith EE, Shobha N, Dai D, Olson DM, Reeves MJ, Saver JL, Hernandez AF, Peterson ED, Fonarow GC, Schwamm LH. Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With The Guidelines-Stroke program. *Circulation*. 2010;122:1496–1504. doi: 10.1161/CIRCULATIONAHA.109.932822
24. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, Peterson ED, Hernandez AF, Fonarow GC, Schwamm LH, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. *Stroke*. 2012;43:2293–2299. doi: 10.1161/STROKEAHA.112.660415
25. Man S, Xian Y, Holmes DN, Matsouaka RA, Saver JL, Smith EE, Bhatt DL, Schwamm LH, Fonarow GC. Association between thrombolytic door-to-needle time and 1-year mortality and readmission in patients with acute ischemic stroke. *JAMA*. 2020;323:2170–2184. doi: 10.1001/jama.2020.5697
26. Fonarow GC, Liang L, Smith EE, Reeves MJ, Saver JL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH; GWTG-Stroke Steering Committee & Investigators. Comparison of performance achievement award recognition with primary stroke center certification for acute ischemic stroke care. *J Am Heart Assoc*. 2013;2:e000451. doi: 10.1161/JAHA.113.000451
27. Song S, Fonarow GC, Olson DM, Liang L, Schulte PJ, Hernandez AF, Peterson ED, Reeves MJ, Smith EE, Schwamm LH, et al. Association of Get With The Guidelines-Stroke program participation and clinical outcomes for medicare beneficiaries with ischemic stroke. *Stroke*. 2016;47:1294–1302. doi: 10.1161/STROKEAHA.115.011874
28. Howard G, Schwamm LH, Donnelly JP, Howard VJ, Jasne A, Smith EE, Rhodes JD, Kissela BM, Fonarow GC, Kleindorfer DO, et al. Participation in Get With The Guidelines-Stroke and its association with quality of care for stroke. *JAMA Neurol*. 2018;75:1331–1337. doi: 10.1001/jamaneurol.2018.2101
29. Adeoye O, Nystrom KV, Yavagal DR, Luciano J, Nogueira RG, Zorowitz RD, Khalessi AA, Bushnell C, Barsan WG, Panagos P, et al. Recommendations for the establishment of stroke systems of care: a 2019 update. *Stroke*. 2019;50:e187–e210. doi: 10.1161/STR.0000000000000173
30. Higashida R, Alberts MJ, Alexander DN, Crocco TJ, Demaerschalk BM, Derdeyn CP, Goldstein LB, Jauch EC, Mayer SA, Meltzer NM, et al; American Heart Association Advocacy Coordinating Committee. Interactions within stroke systems of care: a policy statement from the American Heart Association/American Stroke Association. *Stroke*. 2013;44:2961–2984. doi: 10.1161/STR.0b013e3182a6d2b2
31. Schwamm LH, Pancioli A, Acker JE, Goldstein LB, Zorowitz RD, Shephard TJ, Moyer P, Gorman M, Johnston SC, Duncan PW, et al; American Stroke Association's Task Force on the Development of Stroke Systems. Recommendations for the establishment of stroke systems of care - recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. *Stroke*. 2005;36:690–703. doi: 10.1161/01.STR.0000158165.42884.4F
32. Wattigney WA, Croft JB, Mensah GA, Alberts MJ, Shephard TJ, Gorelick PB, Nilasena DS, Hess DC, Walker MD, Hanley DF Jr, et al; Paul Coverdell National Acute Stroke Registry. Establishing data elements for the Paul Coverdell National Acute Stroke Registry: Part 1: proceedings of an expert panel. *Stroke*. 2003;34:151–156. doi: 10.1161/01.str.0000048160.41821.b5
33. The Joint Commission. Stroke certification program. 2023. Accessed December 17, 2023. <https://www.jointcommission.org/what-we-offer/certification/certifications-by-setting/hospital-certifications/stroke-certification/>
34. Sheth KN, Smith EE, Grau-Sepulveda MV, Kleindorfer D, Fonarow GC, Schwamm LH. Drip and ship thrombolytic therapy for acute ischemic stroke: use, temporal trends, and outcomes. *Stroke*. 2015;46:732–739. doi: 10.1161/STROKEAHA.114.007506
35. Ekdandoy OJ, Saver JL, Fonarow GC, Schwamm LH, Xian Y, Zhao X, Hernandez AF, Peterson ED, Cheng EM. Patterns of emergency medical services use and its association with timely stroke treatment: findings from Get With The Guidelines-Stroke. *Circ Cardiovasc Qual Outcomes*. 2013;6:262–269. doi: 10.1161/CIRCOUTCOMES.113.000089
36. Fonarow GC, Smith EE, Reeves MJ, Pan W, Olson D, Hernandez AF, Peterson ED, Schwamm LH; Get With The Guidelines Steering Committee and Hospitals. Hospital-level variation in mortality and rehospitalization for medicare beneficiaries with acute ischemic stroke. *Stroke*. 2011;42:159–166. doi: 10.1161/STROKEAHA.110.601831
37. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. *Circulation*. 2011;123:750–758. doi: 10.1161/CIRCULATIONAHA.110.974675
38. Fonarow GC, Pan W, Saver JL, Smith EE, Reeves MJ, Broderick JP, Kleindorfer DO, Sacco RL, Olson DM, Hernandez AF, et al. Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. *JAMA*. 2012;308:257–264. doi: 10.1001/jama.2012.7870
39. Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, Schwamm LH; GWTG-Stroke Steering Committee and Investigators. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. *Stroke*. 2010;41:1431–1439. doi: 10.1161/STROKEAHA.110.583815
40. Song S, Saver J. Growth of regional acute stroke systems of care in the United States in the first decade of the 21st century. *Stroke*. 2012;43:1975–1978. doi: 10.1161/STROKEAHA.112.657809
41. Prvu Bettger JA, Kaltenbach L, Reeves MJ, Smith EE, Fonarow GC, Schwamm LH, Peterson ED. Assessing stroke patients for rehabilitation during the acute hospitalization: findings from the Get With The Guidelines-Stroke program. *Arch Phys Med Rehabil*. 2013;94:38–45. doi: 10.1016/j.apmr.2012.06.029
42. Prvu Bettger J, McCoy L, Smith EE, Fonarow GC, Schwamm LH, Peterson ED. Contemporary trends and predictors of postacute service use and routine discharge home after stroke. *J Am Heart Assoc*. 2015;4:e001038. doi: 10.1161/JAHA.114.001038
43. Allen NB, Kaltenbach L, Goldstein LB, Olson DM, Smith EE, Peterson ED, Schwamm L, Lichtman JH. Regional variation in recommended treatments for ischemic stroke and TIA: Get With The Guidelines--Stroke 2003-2010. *Stroke*. 2012;43:1858–1864. doi: 10.1161/STROKEAHA.112.652305
44. Adcock AK, Schwamm LH, Smith EE, Fonarow GC, Reeves MJ, Xu H, Matsouaka RA, Xian Y, Saver JL. Trends in use, outcomes, and disparities in endovascular thrombectomy in US patients with stroke aged 80 years and older compared with younger patients. *JAMA Netw Open*. 2022;5:e2215869. doi: 10.1001/jamanetworkopen.2022.15869
45. Sheriff F, Xu H, Maud A, Gupta V, Vellipuram A, Fonarow GC, Matsouaka RA, Xian Y, Reeves M, Smith EE, et al. Temporal trends in racial and ethnic disparities in endovascular therapy in acute ischemic stroke. *J Am Heart Assoc*. 2022;11:e023212. doi: 10.1161/JAHA.121.023212
46. Demel SL, Reeves M, Xu H, Xian Y, Mac Grory B, Fonarow GC, Matsouaka R, Smith EE, Saver J, Schwamm L. Sex differences in endovascular therapy for ischemic stroke: results from the Get With The Guidelines-Stroke registry. *Stroke*. 2022;53:3099–3106. doi: 10.1161/STROKEAHA.122.038491
47. Raychev R, Sun JL, Schwamm L, Smith EE, Fonarow GC, Messe SR, Xian Y, Chiswell K, Blanco R, Mac Grory B, et al. Performance of thrombectomy-capable, comprehensive, and primary stroke centers in reperfusion therapies for acute ischemic stroke: report from the Get With The Guidelines-Stroke registry. *Circulation*. 2023;148:2019–2028. doi: 10.1161/CIRCULATIONAHA.123.066114
48. American Heart Association. Get With The Guidelines Stroke. 2023. Accessed January 12, 2024. <https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke>
49. American Heart Association. Target stroke. 2023. Accessed August 4, 2023. <https://www.heart.org/en/professional/quality-improvement/target-stroke>

50. Olson DM, Cox M, Constable M, Britz GW, Lin CB, Zimmer LO, Fonarow GC, Schwamm LH, Peterson ED. Development and initial testing of the stroke rapid-treatment readiness tool. *J Neurosci Nurs*. 2014;46:267–273. doi: 10.1097/JNN.0000000000000082
51. Xian Y, Smith EE, Zhao X, Peterson ED, Olson DM, Hernandez AF, Bhatt DL, Saver JL, Schwamm LH, Fonarow GC. Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. *Stroke*. 2014;45:1387–1395. doi: 10.1161/STROKEAHA.113.003898
52. Cadilhac DA, Kim J, Lannin NA, Kapral MK, Schwamm LH, Dennis MS, Norrving B, Meretoja A. National stroke registries for monitoring and improving the quality of hospital care: a systematic review. *Int J Stroke*. 2016;11:28–40. doi: 10.1177/1747493015607523
53. Hsieh FI, Lien LM, Chen ST, Bai CH, Sun MC, Tseng HP, Chen YW, Chen CH, Jeng JS, Tsai SY, et al; Taiwan Stroke Registry Investigators. Get With The Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With The Guidelines-Stroke in Taiwan. *Circulation*. 2010;122:1116–1123. doi: 10.1161/CIRCULATIONAHA.110.936526
54. Wangqin R, Laskowitz DT, Wang Y, Li Z, Wang Y, Liu L, Liang L, Matsouaka RA, Saver JL, Fonarow GC, et al. International comparison of patient characteristics and quality of care for ischemic stroke: analysis of the China National Stroke Registry and the American Heart Association Get With The Guidelines-Stroke program. *J Am Heart Assoc*. 2018;7:e010623. doi: 10.1161/JAHA.118.010623
55. Man S, Cox M, Patel P, Smith EE, Reeves MJ, Saver JL, Bhatt DL, Xian Y, Schwamm LH, Fonarow GC. Differences in acute ischemic stroke quality of care and outcomes by primary stroke center certification organization. *Stroke*. 2017;48:412–419. doi: 10.1161/STROKEAHA.116.014426
56. Leifer D, Bravata DM, Connors JJ 3rd, Hinchey JA, Jauch EC, Johnston SC, Latchaw R, Likosky W, Ogilvy C, Qureshi AI, et al; American Heart Association Special Writing Group of the Stroke Council. Metrics for measuring quality of care in comprehensive stroke centers: detailed follow-up to Brain Attack Coalition comprehensive stroke center recommendations: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011;42:849–877. doi: 10.1161/STR.0b013e318208eb99
57. Reeves MJ, Parker C, Fonarow GC, Smith EE, Schwamm LH. Development of stroke performance measures: definitions, methods, and current measures. *Stroke*. 2010;41:1573–1578. doi: 10.1161/STROKEAHA.109.577171
58. Centers for Medicare Medicaid Services (CMS). Overview of Hospital Inpatient Quality Programs. 2024. Accessed January 7, 2024. <https://qualitynet.cms.gov/inpatient>
59. American Heart Association. Get With The Guidelines® - Stroke Recognition Overview. 2024. Accessed January 7, 2024. <https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/recognition-from-get-with-the-guidelines-stroke>
60. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, Sacco RL, Schwamm LH. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: stroke initiative. *Stroke*. 2011;42:2983–2989. doi: 10.1161/STROKEAHA.111.621342
61. Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. *JAMA*. 2014;311:1632–1640. doi: 10.1001/jama.2014.3203
62. Xian Y, Xu H, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Hernandez AF, Peterson ED, Schwamm LH, Fonarow GC. Achieving more rapid door-to-needle times and improved outcomes in acute ischemic stroke in a nationwide quality improvement intervention. *Stroke*. 2022;53:1328–1338. doi: 10.1161/STROKEAHA.121.035853
63. American Heart Association. Early career investigator research opportunities. 2023. Accessed October 19, 2023. <https://www.heart.org/en/professional/quality-improvement/quality-research-and-publications/early-career-investigator-research-opportunities>
64. American Heart Association. Precision medicine platform. 2023. Accessed December 19, 2023. <https://precision.heart.org/request>
65. Gliklich RE, Leavy MB, Dreyer NA. *Registries for Evaluating Patient Outcomes: A User's Guide*. AHRQ; 2020.
66. Nasir K, Javed Z. From manual to modern: accelerating health care transformation with automated electronic medical record registries. *Circ Cardiovasc Qual Outcomes*. 2023;16:e010379. doi: 10.1161/CIRCOUTCOMES.123.010379
67. Nasir K, Javad Z, Khan SU, Jones SL, Andrieni J. Big data and digital solutions: laying the foundation for cardiovascular population management. *Methodist Debaquey Cardiovasc J*. 2020;16:272–282. doi: 10.14797/mdcj-16-4-272
68. Bhatt DL, Drozda JP Jr, Shahian DM, Chan PS, Fonarow GC, Heidenreich PA, Jacobs JP, Masoudi FA, Peterson ED, Welke KF, et al; Writing Committee Members. ACC/AHA/STS statement on the future of registries and the performance measurement enterprise: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and The Society of Thoracic Surgeons. *Circ Cardiovasc Qual Outcomes*. 2015;8:634–648. doi: 10.1161/HCQ.0000000000000013
69. Bufalino VJ, Masoudi FA, Stranne SK, Horton K, Albert NM, Beam C, Bonow RO, Davenport RL, Girgus M, Fonarow GC, et al; American Heart Association Advocacy Coordinating Committee. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. *Circulation*. 2011;123:2167–2179. doi: 10.1161/CIR.0b013e3182181529
70. Tu JV, Willison DJ, Silver FL, Fang J, Richards JA, Laupacis A, Kapral MK; Investigators in the Registry of the Canadian Stroke Network. Impracticability of informed consent in the Registry of the Canadian Stroke Network. *N Engl J Med*. 2004;350:1414–1421. doi: 10.1056/NEJMs031697
71. Krumholz HM. In the US, patient data privacy is an illusion. *BMJ*. 2023;381:1225. doi: 10.1136/bmj.p1225
72. Ajana B. Digital health and the biopolitics of the Quantified Self. *Digit Health*. 2017;3:2055207616689509. doi: 10.1177/2055207616689509
73. Liddell K, Simon DA, Lucassen A. Patient data ownership: who owns your health? *J Law Biosci*. 2021;8:1s023. doi: 10.1093/jlb/1s023
74. Maddox TM, Albert NM, Borden WB, Curtis LH, Ferguson TB Jr, Kao DP, Marcus GM, Peterson ED, Redberg R, Rumsfeld JS, et al; American Heart Association Council on Quality of Care and Outcomes Research; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; and Stroke Council. The learning healthcare system and cardiovascular care: a scientific statement from the American Heart Association. *Circulation*. 2017;135:e826–e857. doi: 10.1161/CIR.0000000000000480
75. Cadilhac DA, Bravata DM, Bettger JP, Mikulik R, Norrving B, Uvere EO, Owolabi M, Ranta A, Kilkenny MF. Stroke learning health systems: a topical narrative review with case examples. *Stroke*. 2023;54:1148–1159. doi: 10.1161/STROKEAHA.122.036216
76. Eriksen AV, Möller S, Ryg J. Use of GPT-4 to diagnose complex clinical cases. *NEJM AI*. 2023;1. doi: 10.1056/Alp2300031
77. Fryer CE, Luker JA, McDonnell MN, Hillier SL. Self management programmes for quality of life in people with stroke. *Cochrane Database Syst Rev*. 2016;2016:CD010442. doi: 10.1002/14651858.CD010442.pub2
78. Ortiz-Fernández L, Sagastagoya Zabalá J, Gutiérrez-Ruiz A, Imaz-Ayo N, Alava-Menica A, Arana-Arri E. Efficacy and usability of eHealth technologies in stroke survivors for prevention of a new stroke and improvement of self-management: phase III randomized control trial. *Methods Protoc*. 2019;2:50. doi: 10.3390/mps2020050
79. Liu S, Feng W, Chhatbar PY, Liu Y, Ji X, Ovbiagele B. Mobile health as a viable strategy to enhance stroke risk factor control: a systematic review and meta-analysis. *J Neurol Sci*. 2017;378:140–145. doi: 10.1016/j.jns.2017.04.050
80. American Heart Association. Heart and Stroke Helper™ App. 2024. Accessed January 10, 2024. <https://www.stroke.org/en/life-after-stroke/preventing-another-stroke/heart-and-stroke-helper-app>
81. Olaiya MT, Sodhi-Berry N, Dalli LL, Bam K, Thrift AG, Katzenellenbogen JM, Nedkoff L, Kim J, Kilkenny MF. The allure of big data to improve stroke outcomes: review of current literature. *Curr Neurol Neurosci Rep*. 2022;22:151–160. doi: 10.1007/s11910-022-01180-z
82. Ung D, Kim J, Thrift AG, Cadilhac DA, Andrew NE, Sundararajan V, Kapral MK, Reeves M, Kilkenny MF. Promising use of big data to increase the efficiency and comprehensiveness of stroke outcomes research. *Stroke*. 2019;50:1302–1309. doi: 10.1161/STROKEAHA.118.020372
83. Sidney S, Rosamond WD, Howard VJ, Luepker RV; National Forum for Heart Disease and Stroke Prevention. The “heart disease and stroke statistics–2013 update” and the need for a national cardiovascular surveillance system. *Circulation*. 2013;127:21–23. doi: 10.1161/CIRCULATIONAHA.112.155911
84. Ziaeian B, Xu H, Matsouaka RA, Xian Y, Khan Y, Schwamm LS, Smith EE, Fonarow GC. US surveillance of acute ischemic stroke patient characteristics, care quality, and outcomes for 2019. *Stroke*. 2022;53:3386–3393. doi: 10.1161/STROKEAHA.122.039098

85. Medford-Davis LN, Fonarow GC, Bhatt DL, Xu H, Smith EE, Suter R, Peterson ED, Xian Y, Matsouaka RA, Schwamm LH. Impact of insurance status on outcomes and use of rehabilitation services in acute ischemic stroke: findings from Get With The Guidelines-Stroke. *J Am Heart Assoc*. 2016;5:e004282. doi: 10.1161/JAHA.116.004282
86. McGee BT, Seagraves KB, Smith EE, Xian Y, Zhang S, Alhanti B, Matsouaka RA, Reeves M, Schwamm LH, Fonarow GC. Associations of medicaid expansion with access to care, severity, and outcomes for acute ischemic stroke. *Circ Cardiovasc Qual Outcomes*. 2021;14:e007940. doi: 10.1161/CIRCOUTCOMES.121.007940
87. Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, Davey-Smith G, Dennison-Himmelfarb CR, Lauer MS, Lockwood DW, et al; American Heart Association Council on Quality of Care and Outcomes Research, Council on Epidemiology and Prevention, Council on Cardiovascular and Stroke Nursing, Council on Lifestyle and Cardiometabolic Health, and Stroke Council. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2015;132:873–898. doi: 10.1161/CIR.0000000000000228
88. Churchwell K, Elkind MSV, Benjamin RM, Carson AP, Chang EK, Lawrence W, Mills A, Odom TM, Rodriguez CJ, Rodriguez F, et al; American Heart Association. Call to action: structural racism as a fundamental driver of health disparities: a presidential advisory from the American Heart Association. *Circulation*. 2020;142:e454–e468. doi: 10.1161/CIR.0000000000000936
89. James S, Rao SV, Granger CB. Registry-based randomized clinical trials—a new clinical trial paradigm. *Nat Rev Cardiol*. 2015;12:312–316. doi: 10.1038/nrcardio.2015.33
90. American Heart Association. GWTG clinical research studies. 2023. Accessed October 15, 2023. <https://www.heart.org/en/professional/quality-improvement/quality-research-and-publications/clinical-research-studies>
91. Subramanian S, Tangka F, Edwards P, Hoover S, Cole-Beebe M. Developing and testing a cost data collection instrument for noncommunicable disease registry planning. *Cancer Epidemiol*. 2016;45(suppl 1):S4–S12. doi: 10.1016/j.canep.2016.10.003
92. Strlicuc S, Grad DA, Radu C, Chira D, Stan A, Ungureanu M, Gheorghe A, Muresanu FD. The economic burden of stroke: a systematic review of cost of illness studies. *J Med Life*. 2021;14:606–619. doi: 10.25122/jml-2021-0361
93. Luengo-Fernandez R, Gray AM, Rothwell PM. Costs of stroke using patient-level data: a critical review of the literature. *Stroke*. 2009;40:e18–e23. doi: 10.1161/STROKEAHA.108.529776
94. Bettger JP, Cadilhac DA. Stroke care costs and cost-effectiveness to inform health policy. *Stroke*. 2022;53:2078–2081. doi: 10.1161/STROKEAHA.122.037451
95. Rajsic S, Gothe H, Borba HH, Sroczynski G, Vujcic J, Toell T, Siebert U. Economic burden of stroke: a systematic review on post-stroke care. *Eur J Health Econ*. 2019;20:107–134. doi: 10.1007/s10198-018-0984-0